As the numbers of COVID-19 cases are rising across the world, India has three vaccine candidates which are in different phases of clinical study, as informed by Indian Council of Medical Research (ICMR). Studies for Phase 1 and 2 are to determine the safety and very early efficacy of the novel coronavirus.
The first vaccine COVAXIN, developed by Bharat Biotech in collaboration with ICMR has completed its first phase on eleven sites and is now undergoing the second phase of clinical trial.
Bharat Biotech has completed phase I of clinical trials while the Oxford vaccine to be manufactured by Serum Institute of India has commenced clinical trials at 17 sites.The second is a DNA vaccine called Zydus Cadila. The phase I study of the vaccine in India is completed and it has begun its phase II study at eleven sites.
The third is a recombinant Oxford University vaccine manufactured by Serum Institute of India. It has acquired approval from DCGI to conduct phase II and phase III of clinical trials. The clinical trials in the country have already started at seventeen different sites.